Eventide Asset Management, LLC Prothena Corp Public LTD CO Transaction History

Eventide Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$48.26 - $78.59 $309,973 - $504,783	6,423 Added 1.46%	445,155 $30.4 Million
Q4 2022 Feb 13, 2023	BUY	$52.05 - $65.0 $10.9 Million - $13.6 Million	208,732 Added 90.75%	438,732 $26.4 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $5.79 Million - $13.9 Million	230,000 New	230,000 $13.9 Million
Q2 2018 Aug 14, 2018	SELL	$10.99 - $44.21 $406,630 - $1.64 Million	-37,000 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$27.95 - $45.04 $2.32 Million - $3.74 Million	-83,000 Reduced 69.17%	37,000 $1.36 Million
Q3 2017 Nov 14, 2017	BUY	$53.83 - $67.75 $6.46 Million - $8.13 Million	120,000	120,000 $7.77 Million

185

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $668M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.